메뉴 건너뛰기




Volumn 35, Issue 6, 2017, Pages 591-597

Erratum: Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: The alliance A031203 CABOSUN trial (Journal of Clinical Oncology (2017) 35 (591-597) DOI: 10.1200/JCO.2016.70.7398);Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: The alliance A031203 CABOSUN trial

(13)  Choueiri, Toni K a   Halabi, Susan c   Sanford, Ben L c   Hahn, Olwen e   Michaelson, M Dror b   Walsh, Meghara K a   Feldman, Darren R f   Olencki, Thomas g   Picus, Joel h   Small, Eric J i   Dakhil, Shaker j   George, Daniel J d   Morris, Michael J f  


Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CABOZANTINIB; SUNITINIB; ANILIDE; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE;

EID: 85013276177     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.76.3292     Document Type: Erratum
Times cited : (594)

References (31)
  • 1
    • 73349084973 scopus 로고    scopus 로고
    • Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study
    • Heng DY, Xie W, Regan MM, et al: Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study. J Clin Oncol 27:5794-5799, 2009
    • (2009) J Clin Oncol , vol.27 , pp. 5794-5799
    • Heng, D.Y.1    Xie, W.2    Regan, M.M.3
  • 2
    • 0032772880 scopus 로고    scopus 로고
    • Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma
    • Motzer RJ, Mazumdar M, Bacik J, et al: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530-2540, 1999
    • (1999) J Clin Oncol , vol.17 , pp. 2530-2540
    • Motzer, R.J.1    Mazumdar, M.2    Bacik, J.3
  • 4
    • 84955488717 scopus 로고    scopus 로고
    • Updated EAU guidelines for clear cell renal cancer patients who fail VEGF targeted therapy
    • Powles T, Staehler M, Ljungberg B, et al: Updated EAU guidelines for clear cell renal cancer patients who fail VEGF targeted therapy. Eur Urol 69:4-6, 2016
    • (2016) Eur Urol , vol.69 , pp. 4-6
    • Powles, T.1    Staehler, M.2    Ljungberg, B.3
  • 5
    • 84969523091 scopus 로고    scopus 로고
    • Prescribing preferences in the first-line treatment for patients with metastatic renal cell carcinoma in the United States
    • Hackshaw MD, Holmes M, Lankford M, et al: Prescribing preferences in the first-line treatment for patients with metastatic renal cell carcinoma in the United States. Clin Genitourin Cancer 14:e479-e487, 2016
    • (2016) Clin Genitourin Cancer , vol.14 , pp. e479-e487
    • Hackshaw, M.D.1    Holmes, M.2    Lankford, M.3
  • 6
    • 84975268061 scopus 로고    scopus 로고
    • Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma
    • Carlo MI, Voss MH, Motzer RJ: Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. Nat Rev Urol 13:420-431, 2016
    • (2016) Nat Rev Urol , vol.13 , pp. 420-431
    • Carlo, M.I.1    Voss, M.H.2    Motzer, R.J.3
  • 7
    • 84882781441 scopus 로고    scopus 로고
    • Pazopanib versus sunitinib in metastatic renal-cell carcinoma
    • Motzer RJ, Hutson TE, Cella D, et al: Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369:722-731, 2013
    • (2013) N Engl J Med , vol.369 , pp. 722-731
    • Motzer, R.J.1    Hutson, T.E.2    Cella, D.3
  • 8
    • 33846181370 scopus 로고    scopus 로고
    • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
    • Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007
    • (2007) N Engl J Med , vol.356 , pp. 115-124
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 9
    • 77949890945 scopus 로고    scopus 로고
    • Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial
    • Sternberg CN, Davis ID, Mardiak J, et al: Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 28:1061-1068, 2010
    • (2010) J Clin Oncol , vol.28 , pp. 1061-1068
    • Sternberg, C.N.1    Davis, I.D.2    Mardiak, J.3
  • 10
    • 84901844215 scopus 로고    scopus 로고
    • First-, second-, third-line therapy for mRCC: Benchmarks for trial design from the IMDC
    • Ko JJ, Choueiri TK, Rini BI, et al: First-, second-, third-line therapy for mRCC: Benchmarks for trial design from the IMDC. Br J Cancer 110:1917-1922, 2014
    • (2014) Br J Cancer , vol.110 , pp. 1917-1922
    • Ko, J.J.1    Choueiri, T.K.2    Rini, B.I.3
  • 11
    • 55949101858 scopus 로고    scopus 로고
    • Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen
    • Bommi-Reddy A, Almeciga I, Sawyer J, et al: Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci USA 105:16484-16489, 2008
    • (2008) Proc Natl Acad Sci USA , vol.105 , pp. 16484-16489
    • Bommi-Reddy, A.1    Almeciga, I.2    Sawyer, J.3
  • 12
    • 0037478437 scopus 로고    scopus 로고
    • Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
    • Pennacchietti S, Michieli P, Galluzzo M, et al: Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3: 347-361, 2003
    • (2003) Cancer Cell , vol.3 , pp. 347-361
    • Pennacchietti, S.1    Michieli, P.2    Galluzzo, M.3
  • 13
    • 84907192193 scopus 로고    scopus 로고
    • Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET
    • Rankin EB, Fuh KC, Castellini L, et al: Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. Proc Natl Acad Sci USA 111:13373-13378, 2014
    • (2014) Proc Natl Acad Sci USA , vol.111 , pp. 13373-13378
    • Rankin, E.B.1    Fuh, K.C.2    Castellini, L.3
  • 14
    • 84939262957 scopus 로고    scopus 로고
    • Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma
    • Yu H, Liu R, Ma B, et al: Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma. Br J Cancer 113:616-625, 2015
    • (2015) Br J Cancer , vol.113 , pp. 616-625
    • Yu, H.1    Liu, R.2    Ma, B.3
  • 15
    • 84873832718 scopus 로고    scopus 로고
    • c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma
    • Gibney GT, Aziz SA, Camp RL, et al: c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol 24: 343-349, 2013
    • (2013) Ann Oncol , vol.24 , pp. 343-349
    • Gibney, G.T.1    Aziz, S.A.2    Camp, R.L.3
  • 16
    • 68049096311 scopus 로고    scopus 로고
    • Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival
    • Gustafsson A, Martuszewska D, Johansson M, et al: Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clin Cancer Res 15:4742-4749, 2009
    • (2009) Clin Cancer Res , vol.15 , pp. 4742-4749
    • Gustafsson, A.1    Martuszewska, D.2    Johansson, M.3
  • 17
    • 84961287855 scopus 로고    scopus 로고
    • Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models
    • Ciamporcero E, Miles KM, Adelaiye R, et al: Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Mol Cancer Ther 14:101-110, 2015
    • (2015) Mol Cancer Ther , vol.14 , pp. 101-110
    • Ciamporcero, E.1    Miles, K.M.2    Adelaiye, R.3
  • 18
    • 84941670032 scopus 로고    scopus 로고
    • Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
    • Zhou L, Liu XD, Sun M, et al: Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene 35:2687-2697, 2016
    • (2016) Oncogene , vol.35 , pp. 2687-2697
    • Zhou, L.1    Liu, X.D.2    Sun, M.3
  • 19
    • 83355166909 scopus 로고    scopus 로고
    • Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth
    • Yakes FM, Chen J, Tan J, et al: Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 10:2298-2308, 2011
    • (2011) Mol Cancer Ther , vol.10 , pp. 2298-2308
    • Yakes, F.M.1    Chen, J.2    Tan, J.3
  • 20
    • 84946552683 scopus 로고    scopus 로고
    • Cabozantinib versus everolimus in advanced renal-cell carcinoma
    • Choueiri TK, Escudier B, Powles T, et al: Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1814-1823, 2015
    • (2015) N Engl J Med , vol.373 , pp. 1814-1823
    • Choueiri, T.K.1    Escudier, B.2    Powles, T.3
  • 21
    • 84991063392 scopus 로고    scopus 로고
    • Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): Final results from a randomised, open-label, phase 3 trial
    • Choueiri TK, Escudier B, Powles T, et al: Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): Final results from a randomised, open-label, phase 3 trial. Lancet Oncol 17:917-927, 2016
    • (2016) Lancet Oncol , vol.17 , pp. 917-927
    • Choueiri, T.K.1    Escudier, B.2    Powles, T.3
  • 22
    • 57849117384 scopus 로고    scopus 로고
    • New response evaluation criteria in solid tumours: Revised RECIST guideline
    • version 1.1
    • Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
    • (2009) Eur J Cancer , vol.45 , pp. 228-247
    • Eisenhauer, E.A.1    Therasse, P.2    Bogaerts, J.3
  • 24
    • 84856159566 scopus 로고    scopus 로고
    • Targeted therapies for renal cell carcinoma: Review of adverse event management strategies
    • Eisen T, Sternberg CN, Robert C, et al: Targeted therapies for renal cell carcinoma: Review of adverse event management strategies. J Natl Cancer Inst 104:93-113, 2012
    • (2012) J Natl Cancer Inst , vol.104 , pp. 93-113
    • Eisen, T.1    Sternberg, C.N.2    Robert, C.3
  • 25
    • 85007476856 scopus 로고    scopus 로고
    • Contemporary treatment of metastatic renal cell carcinoma
    • Stukalin I, Alimohamed N, Heng DY: Contemporary treatment of metastatic renal cell carcinoma. Oncol Rev 10:295, 2016
    • (2016) Oncol Rev , vol.10 , pp. 295
    • Stukalin, I.1    Alimohamed, N.2    Heng, D.Y.3
  • 26
    • 79953307244 scopus 로고    scopus 로고
    • Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib
    • Beuselinck B, Oudard S, Rixe O, et al: Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 22:794-800, 2011
    • (2011) Ann Oncol , vol.22 , pp. 794-800
    • Beuselinck, B.1    Oudard, S.2    Rixe, O.3
  • 27
    • 84879689379 scopus 로고    scopus 로고
    • Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
    • Motzer RJ, Escudier B, Bukowski R, et al: Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. Br J Cancer 108:2470-2477, 2013
    • (2013) Br J Cancer , vol.108 , pp. 2470-2477
    • Motzer, R.J.1    Escudier, B.2    Bukowski, R.3
  • 28
    • 84895059211 scopus 로고    scopus 로고
    • Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy
    • McKay RR, Kroeger N, Xie W, et al: Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol 65:577-584, 2014
    • (2014) Eur Urol , vol.65 , pp. 577-584
    • McKay, R.R.1    Kroeger, N.2    Xie, W.3
  • 29
    • 84946607195 scopus 로고    scopus 로고
    • Nivolumab versus everolimus in advanced renal-cell carcinoma
    • Motzer RJ, Escudier B, McDermott DF, et al: Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803-1813, 2015
    • (2015) N Engl J Med , vol.373 , pp. 1803-1813
    • Motzer, R.J.1    Escudier, B.2    McDermott, D.F.3
  • 30
    • 84920828671 scopus 로고    scopus 로고
    • Dual effectsof atargeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine
    • Kwilas AR, Ardiani A, Donahue RN, et al: Dual effectsof atargeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. J Transl Med 12:294, 2014
    • (2014) J Transl Med , vol.12 , pp. 294
    • Kwilas, A.R.1    Ardiani, A.2    Donahue, R.N.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.